Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen rep's description of KRAS information as predictive of response to the colorectal cancer drug during a ASHP meeting draws a notice of violation from FDA.
Advertisement

Related Content

DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
Pfizer Whistleblower Suit Alleges Sales Reps Had Targets For Rapamune Off-Label Uses
FDA Deputizes Doctors In Hunt For "Bad Ads"
“DDMAC Watch” Challenges FDA Authority Over Sales Reps’ Statements
“DDMAC Watch” Challenges FDA Authority Over Sales Reps’ Statements

Topics

Advertisement
UsernamePublicRestriction

Register

PS070681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel